Precigen, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PGEN | AUTL | IMTX | IDYA | XNCR | LEGN | |
|---|---|---|---|---|---|---|
| Market cap | 1.81B | 367.30M | 1.05B | 3.13B | 2.60B | 4.43B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -23.0 | -2.2 | -3.4 | -7.9 | -9.9 | 21.7 |
| Price/book | 85.7 | 4.9 | 2.1 | 2.9 | 4.0 | 3.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +31.58% | +1.47% | −20.86% | +8.41% | +150.21% | −29.66% |
| Today | −3.71% | −2.47% | −2.33% | +3.29% | +14.33% | +6.01% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All PGEN news ›Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance
Nov 04, 2026, 16:05 ET GERMANTOWN, Md., Nov. 4, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of…
Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4
/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines... GERMANTOWN, Md., Oct. 28, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN),…
Precigen craters on Inovio Voceryq immunotherapy approval
Precigen stock sank after FDA approved Inovio's rival recurrent respiratory papillomatosis therapy Voceryq. Read more here. - Precigen is down ~25% in Monday trading following the Oct. 30 after-market close announcement that Inovio…
FDA Grants Accelerated Approval to Inovio's DNA Immunotherapy Voceryq; Precigen Shares Plunge 27% After Hours
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Inovio Pharmaceuticals' (Nasdaq: INO) DNA-based immunotherapy Voceryq (development name INO-3107) for adult patients with recurrent respiratory papillomatosis…
PepGen: Maintaining 'Hold,' PGN-EDODM1 Data Is A Major Inflection Point
PepGen stays a hold, after a major problem with its released data from the phase 2 FREEDOM2-DM1 study using the PGN-EDODM1 study. Read more on PEPG stock here. - PepGen remains a "Hold" after mixed phase 2 MAD data for PGN-EDODM1 in DM1,…
Precigen (NASDAQ:PGEN) Stock Rating Cut to Buy at Wall Street Zen
Posted by Defense World Staff on Oct 31st, 2026 Precigen (NASDAQ:PGEN – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Saturday,…
Prenosis Announces $20M BARDA Contract and $20M Series A Financing Round, Advancing Mission to Deliver Integrated Diagnostics and Therapeutics
Jan 29, 2026, 10:05 ET Bobby Reddy, Jr., PhD, Prenosis CEO and co-founder explains, "Because of these investments, we are well-positioned to advance the development of biology-driven solutions that can transform outcomes for patients…
From Bethesda Magazine: Germantown biotech Precigen develops treatments for rare diseases
The company’s Papzimeos drug treats recurrent respiratory papillomatosis, which can cause tumors on the vocal cords, trachea Editor’s note: This is the second in a six-story series about local companies doing innovative work. Aledade was…
Pyxis Oncology (NASDAQ:PYXS) & Precigen (NASDAQ:PGEN) Head to Head Analysis
Posted by Defense World Staff on Oct 10th, 2026 Precigen (NASDAQ:PGEN – Get Free Report) and Pyxis Oncology (NASDAQ:PYXS – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two…
PRME Stock Climbs As FDA Greenlights Gene-Editing Trials
Prime Medicine Inc. stocks have been trading up by 8.88 percent amid heightened investor optimism over its gene-editing pipeline. PRME is trading like a classic high-risk, high-reward biotech. Over the last few weeks, Prime Medicine shares…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- prnewswire.com3
- defenseworld.net2
- seekingalpha.com2
- bethesdamagazine.com1
- finance.biggo.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.